Inventor
PAN CLARK
US41 patents
⚠️ This page may combine multiple inventors who share the name “PAN CLARK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GENZYME CORP
20 patentsUS9790268B2Oct 17, 2017
Fc containing polypeptides with altered glycosylation and reduced effector function
GENZYME CORP29 citations94
US10494439B2Dec 3, 2019
Hyperglycosylated binding polypeptides
GENZYME CORP9 citations92
US10214589B2Feb 26, 2019
Site-specific antibody-drug conjugation through glycoengineering
GENZYME CORP9 citations92
US9701753B2Jul 11, 2017
Hyperglycosylated binding polypeptides
GENZYME CORP16 citations92
US9580511B2Feb 28, 2017
Site-specific antibody-drug conjugation through glycoengineering
GENZYME CORP17 citations92
US10836813B2Nov 17, 2020
Fc containing polypeptides with altered glycosylation and reduced effector function
GENZYME CORP11 citations86
US11807690B2Nov 7, 2023
Hyperglycosylated binding polypeptides
GENZYME CORP4 citations85
US11325971B2May 10, 2022
scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity
GENZYME CORP4 citations83
US11130816B2Sep 28, 2021
Site-specific antibody-drug conjugation through glycoengineering
GENZYME CORP6 citations83
US10995148B2May 4, 2021
Site-specific glycoengineering of targeting moieties
GENZYME CORP8 citations83
US10508146B2Dec 17, 2019
ScFv-Fc dimers that bind transforming growth factor-BETA1 with high affinity, avidity and specificity
GENZYME CORP4 citations83
US11186638B2Nov 30, 2021
Anti-αβTCR antibody
GENZYME CORP10 citations82
US10308917B2Jun 4, 2019
Nucleotide sequences encoding VEGF antagonist compositions of FLT-1 and uses thereof
GENZYME CORP7 citations82
US12110338B2Oct 8, 2024
Site-specific antibody-drug conjugation through glycoengineering
GENZYME CORP2 citations72
US11976112B2May 7, 2024
scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity
GENZYME CORP1 citations72
US12503498B2Dec 23, 2025
Fc containing polypeptides with altered glycosylation and reduced effector function
GENZYME CORP0 citations62
US12473356B2Nov 18, 2025
scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity
GENZYME CORP0 citations61
US11697690B2Jul 11, 2023
Site-specific glycoengineering of targeting moieties
GENZYME CORP1 citations61
US10730936B2Aug 4, 2020
Engineered anti-TGF-β antibodies and antigen-binding fragments
GENZYME CORP0 citations48
US9783604B2Oct 10, 2017
Engineered anti-TGF-beta antibodies and antigen-binding fragments
GENZYME CORP1 citations48
BAYER PHARMACEUTICALS CORP
7 patentsUS6972319B1Dec 6, 2005
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
BAYER PHARMACEUTICALS CORP17 citations92
US7041646B2May 9, 2006
Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
BAYER PHARMACEUTICALS CORP43 citations91
US6864069B2Mar 8, 2005
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
BAYER PHARMACEUTICALS CORP34 citations91
US7494978B2Feb 24, 2009
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
BAYER PHARMACEUTICALS CORP0 citations50
US7488715B2Feb 10, 2009
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
BAYER PHARMACEUTICALS CORP0 citations50
US7488716B2Feb 10, 2009
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
BAYER PHARMACEUTICALS CORP0 citations50
US7488714B2Feb 10, 2009
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
BAYER PHARMACEUTICALS CORP0 citations50
BAYER HEALTHCARE LLC
3 patentsUS7432364B2Oct 7, 2008
Human TIMP-1 antibodies
BAYER HEALTHCARE LLC18 citations89
US7399745B2Jul 15, 2008
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
BAYER HEALTHCARE LLC0 citations50
US7993849B2Aug 9, 2011
Human TIMP-1 antibodies
BAYER HEALTHCARE LLC0 citations49
TAKEDA PHARMACEUTICALS CO
3 patentsUS11660328B2May 30, 2023
GLP-2 analogs and peptibodies for administration before, during or after surgery
TAKEDA PHARMACEUTICALS CO2 citations67
US12291556B2May 6, 2025
Parathyroid hormone variants
TAKEDA PHARMACEUTICALS CO0 citations56
US11685912B2Jun 27, 2023
Affinity purification of glycosidase-cleaving enzymes
TAKEDA PHARMACEUTICALS CO0 citations50